奥洛组单抗对活动性类风湿关节炎患者CYP酶活性的影响
本研究在17例活动性类风湿关节炎患者中,单次皮下注射128 mg奥洛组单抗前后,用鸡尾酒法评估CYP3A4、CYP2C19、CYP2C9和CYP1A2探针底物的药代动力学。结果显示奥洛组单抗使咪达唑仑和奥美拉唑暴露分别降低30-33%和26-32%,咖啡因暴露增加19-23%,S-华法林无显著变化。结论认为奥洛组单抗可能逆转IL-6对CYP3A4和CYP2C19的抑制,按FDA指南为CYP3A4和CYP2C19的弱诱导剂。
要点
- 奥洛组单抗可能逆转IL-6对CYP3A4和CYP2C19的抑制,属于弱诱导剂。
- 合用CYP3A4或CYP2C19底物时需关注底物暴露下降的风险。
- CYP2C9和CYP1A2底物受奥洛组单抗影响较小,但咖啡因暴露有所增加。
核心结论
- 在活动性类风湿关节炎患者中,奥洛组单抗可能逆转IL-6介导的CYP3A4和CYP2C19抑制,按FDA指南为CYP3A4和CYP2C19的弱诱导剂。
研究设计与样本
- 17例活动性类风湿关节炎患者口服咪达唑仑、奥美拉唑、华法林和咖啡因鸡尾酒,单用及单次皮下注射128 mg奥洛组单抗2周后分别给药,采用非房室分析计算药代动力学参数。
主要发现
- 单次给予奥洛组单抗后,咪达唑仑暴露较单用鸡尾酒时下降30-33%,奥美拉唑暴露下降26-32%。
- 奥洛组单抗存在时,咖啡因暴露较单用咖啡因时增加19-23%。
- S-华法林暴露无显著变化。
临床怎么用
- 合用奥洛组单抗时,应关注CYP3A4和CYP2C19底物暴露下降可能导致的疗效降低。
- 对CYP3A4或CYP2C19底物治疗窗窄者,可考虑监测疗效或调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In patients with rheumatoid arthritis (RA), interleukin (IL)-6 affects the activity of cytochrome P450 (CYP) enzymes. Treatment with anti-IL-6 therapy can reverse the IL-6-mediated downregulation of CYP enzymes, resulting in changes in plasma levels of CYP substrates. The primary objective of this study was to evaluate the impact of the IL-6 inhibitor olokizumab on the pharmacokinetics of CYP probe substrates in subjects with active RA. METHODS: Seventeen patients with active RA were orally administered a phenotyping cocktail of midazolam (CYP3A4 substrate), omeprazole (CYP2C19 substrate), warfarin (CYP2C9 substrate) and caffeine (CYP1A2 substrate) alone and 2 weeks after a single subcutaneous injection of 128 mg olokizumab. The pharmacokinetic parameters of each substrate were calculated using noncompartmental analysis. RESULTS: Sixteen of 17 enrolled patients received the complete doses of the cocktail drugs and olokizumab and were eligible for the pharmacokinetic evaluations. After single-dose administration of olokizumab, the exposure of midazolam and omeprazole decreased by 30-33% and 26-32%, respectively, compared to when the substrates were administered along via cocktail. In the presence of olokizumab, caffeine exposure increased by 19-23% compared to caffeine administration alone. There were no significant changes in S-warfarin exposure. CONCLUSION: In patients with active RA, olokizumab potentially reverses the IL-6-mediated suppression of CYP3A4 and CYP2C19. According to FDA guidance, olokizumab is considered a weak inducer of CYP3A4 and CYP2C19.
引用
- Agachi S, Beloukhova M, Mould D, et al. Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2024. PMID: 38984761. doi:10.1111/bcp.16175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。